A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.
Checked against the public recordLast updated Sep 8, 2016 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Merrimack Pharmaceuticals
- Interventions being studied
- Drug: MM-121; Drug: Irinotecan; Drug: Cetuximab
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * No standard options remaining * Adequate liver and kidney functions * 18 years of age or above Exclusion Criteria: * History of any secondary active cancer in the last 3 years. * Pregnant or breast feeding * History of severe allergic reactions or contraindications to cetuximab or irinotecan
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Study locationSan Francisco, California
- Study locationBoston, Massachusetts
- Study locationChapel Hill, North Carolina
- Study locationSalt Lake City, Utah
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 8, 2016. Always confirm current availability with the study team.